Literature DB >> 7702969

Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET.

M Itoh1, K Meguro, T Fujiwara, J Hatazawa, R Iwata, K Ishiwata, T Takahashi, T Ido, H Sasaki.   

Abstract

By means of positron emission tomography (PET) and 18F-fluorodopa (FDOPA), a study was initiated to analyze the cerebral dopamine (DA) metabolism of 32 subjects including those with AD/SDAT and vascular dementia (VD, multi-infarct type). A semiautomated irregular ROI drawing routine to identify the striatum was developed that interactively defined the PET threshold pixels referring to the count histograms and location of the corresponding pixels. A comparative study by five examiners showed significant improvement in the area size definition and count linearity particularly for low contrast objects. The graphical plot was employed to calculate the FDOPA influx rate (Ki) for the ROI data with cerebellar radioactivity as an input function. The striatal Ki value was found to be relatively stable and did not show signs of a significant age-related change. The vascular patients had smaller Ki to the striatum than the aged control. Although the mean Ki of AD/SDAT was almost compatible with that of age-matched normals, their Ki was more scattered with higher and lower Ki cases. The multiple regression analysis revealed that the Ki could be predicted by age and the mini-mental state (MMS) performance (r2 = 0.590, p < 0.01 for AD/SDAT, r2 = 0.401, and p < 0.05 for VD). MMS was found to be a more dominant factor than age. We conclude that dopamine metabolism became disturbed as dementia became progressively severe.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7702969     DOI: 10.1007/bf03165027

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  21 in total

1.  Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

Authors:  K L Leenders; A J Palmer; N Quinn; J C Clark; G Firnau; E S Garnett; C Nahmias; T Jones; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-08       Impact factor: 10.154

2.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

3.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

4.  Cerebrovascular responsiveness to hypercapnia in Alzheimer's dementia and vascular dementia of the Binswanger type.

Authors:  Y Kuwabara; Y Ichiya; M Otsuka; K Masuda; A Ichimiya; M Fujishima
Journal:  Stroke       Date:  1992-04       Impact factor: 7.914

5.  Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type.

Authors:  P J Tyrrell; G V Sawle; V Ibanez; P M Bloomfield; K L Leenders; R S Frackowiak; M N Rossor
Journal:  Arch Neurol       Date:  1990-12

6.  Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia.

Authors:  A Carlsson; B Winblad
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

7.  6-[18F]fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography.

Authors:  H Nagasawa; H Saito; K Kogure; J Hatazawa; M Itoh; T Fujiwara; S Watanuki; S Seo; R Iwata; T Ido
Journal:  J Neurol Sci       Date:  1993-04       Impact factor: 3.181

Review 8.  Cerebral circulation in the elderly.

Authors:  J S Meyer; Y Terayama; S Takashima
Journal:  Cerebrovasc Brain Metab Rev       Date:  1993

9.  Striatal dopamine distribution in parkinsonian patients during life.

Authors:  C Nahmias; E S Garnett; G Firnau; A Lang
Journal:  J Neurol Sci       Date:  1985-07       Impact factor: 3.181

10.  Metabolites of 6-[18F]fluoro-L-dopa in human blood.

Authors:  G Firnau; S Sood; R Chirakal; C Nahmias; E S Garnett
Journal:  J Nucl Med       Date:  1988-03       Impact factor: 10.057

View more
  7 in total

Review 1.  Aspiration and infection in the elderly : epidemiology, diagnosis and management.

Authors:  Masayuki Kikawada; Toshihiko Iwamoto; Masaru Takasaki
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

3.  Experience of 6-l-[18F]FDOPA Production Using Commercial Disposable Cassettes and an Automated Module.

Authors:  Raviteja Nanabala; Maroor Raghavan Ambikalmajan Pillai; Buvaneswari Gopal
Journal:  Nucl Med Mol Imaging       Date:  2022-04-06

4.  Protective Effects of Ferulic Acid against Chronic Cerebral Hypoperfusion-Induced Swallowing Dysfunction in Rats.

Authors:  Takashi Asano; Hirokazu Matsuzaki; Naohiro Iwata; Meiyan Xuan; Shinya Kamiuchi; Yasuhide Hibino; Takeshi Sakamoto; Mari Okazaki
Journal:  Int J Mol Sci       Date:  2017-03-03       Impact factor: 5.923

5.  24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.

Authors:  Myuri Ruthirakuhan; Nathan Herrmann; Ana C Andreazza; Nicolaas Paul L G Verhoeff; Damien Gallagher; Sandra E Black; Alex Kiss; Krista L Lanctôt
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 6.  Use of ACE inhibitors and risk of community-acquired pneumonia: a review.

Authors:  Petros I Rafailidis; Dimitrios K Matthaiou; Ioannis Varbobitis; Matthew E Falagas
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 3.064

Review 7.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.